Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease

Yijun Pan, Kotaro Omori, Izna Ali, Masanori Tachikawa, Tetsuya Terasaki, Kim L.R. Brouwer, Joseph A. Nicolazzo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

It is well established that the expression and function of drug transporters at the blood-brain barrier are altered in Alzheimer's disease (AD). However, we recently demonstrated in a mouse model of AD that the expression of key drug transporters and metabolizing enzymes was modified in peripheral organs, such as the small intestine and liver, suggesting that systemic drug absorption may be altered in AD. The purpose of this study was to determine whether the expression of drug transporters in the kidneys differed between 8- to 9-month-old wild-type mice and APPswe/PSEN1dE9 (APP/PS1) transgenic mice, a mouse model of familial AD, using a quantitative targeted absolute proteomics approach. The protein expression of the drug transporters—multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2—was upregulated 1.6-, 1.3-, and 1.4-fold, respectively, in kidneys from APP/PS1 mice relative to wild-type mice. These results suggest that in addition to modified oral absorption of certain drugs, it is possible that the renal excretion of drugs that are multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2 substrates could be altered in AD. These changes could affect the interpretation of studies conducted during drug development using this mouse model of AD and potentially impact dosage regimens of such drugs prescribed in this patient population.

Original languageEnglish
Pages (from-to)2484-2489
Number of pages6
JournalJournal of Pharmaceutical Sciences
Volume108
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Alzheimer's disease
  • multidrug resistance-associated protein(s) (MDR)
  • organic anion transporter(s) (OAT)
  • organic cation transporter(s) (OCT)
  • renal transport
  • transporters

Cite this

Pan, Yijun ; Omori, Kotaro ; Ali, Izna ; Tachikawa, Masanori ; Terasaki, Tetsuya ; Brouwer, Kim L.R. ; Nicolazzo, Joseph A. / Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease. In: Journal of Pharmaceutical Sciences. 2019 ; Vol. 108, No. 7. pp. 2484-2489.
@article{821235ae0cf04d0db8fcb59cf114ffd2,
title = "Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease",
abstract = "It is well established that the expression and function of drug transporters at the blood-brain barrier are altered in Alzheimer's disease (AD). However, we recently demonstrated in a mouse model of AD that the expression of key drug transporters and metabolizing enzymes was modified in peripheral organs, such as the small intestine and liver, suggesting that systemic drug absorption may be altered in AD. The purpose of this study was to determine whether the expression of drug transporters in the kidneys differed between 8- to 9-month-old wild-type mice and APPswe/PSEN1dE9 (APP/PS1) transgenic mice, a mouse model of familial AD, using a quantitative targeted absolute proteomics approach. The protein expression of the drug transporters—multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2—was upregulated 1.6-, 1.3-, and 1.4-fold, respectively, in kidneys from APP/PS1 mice relative to wild-type mice. These results suggest that in addition to modified oral absorption of certain drugs, it is possible that the renal excretion of drugs that are multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2 substrates could be altered in AD. These changes could affect the interpretation of studies conducted during drug development using this mouse model of AD and potentially impact dosage regimens of such drugs prescribed in this patient population.",
keywords = "Alzheimer's disease, multidrug resistance-associated protein(s) (MDR), organic anion transporter(s) (OAT), organic cation transporter(s) (OCT), renal transport, transporters",
author = "Yijun Pan and Kotaro Omori and Izna Ali and Masanori Tachikawa and Tetsuya Terasaki and Brouwer, {Kim L.R.} and Nicolazzo, {Joseph A.}",
year = "2019",
month = "7",
doi = "10.1016/j.xphs.2019.02.016",
language = "English",
volume = "108",
pages = "2484--2489",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "Elsevier",
number = "7",

}

Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease. / Pan, Yijun; Omori, Kotaro; Ali, Izna; Tachikawa, Masanori; Terasaki, Tetsuya; Brouwer, Kim L.R.; Nicolazzo, Joseph A.

In: Journal of Pharmaceutical Sciences, Vol. 108, No. 7, 07.2019, p. 2484-2489.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease

AU - Pan, Yijun

AU - Omori, Kotaro

AU - Ali, Izna

AU - Tachikawa, Masanori

AU - Terasaki, Tetsuya

AU - Brouwer, Kim L.R.

AU - Nicolazzo, Joseph A.

PY - 2019/7

Y1 - 2019/7

N2 - It is well established that the expression and function of drug transporters at the blood-brain barrier are altered in Alzheimer's disease (AD). However, we recently demonstrated in a mouse model of AD that the expression of key drug transporters and metabolizing enzymes was modified in peripheral organs, such as the small intestine and liver, suggesting that systemic drug absorption may be altered in AD. The purpose of this study was to determine whether the expression of drug transporters in the kidneys differed between 8- to 9-month-old wild-type mice and APPswe/PSEN1dE9 (APP/PS1) transgenic mice, a mouse model of familial AD, using a quantitative targeted absolute proteomics approach. The protein expression of the drug transporters—multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2—was upregulated 1.6-, 1.3-, and 1.4-fold, respectively, in kidneys from APP/PS1 mice relative to wild-type mice. These results suggest that in addition to modified oral absorption of certain drugs, it is possible that the renal excretion of drugs that are multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2 substrates could be altered in AD. These changes could affect the interpretation of studies conducted during drug development using this mouse model of AD and potentially impact dosage regimens of such drugs prescribed in this patient population.

AB - It is well established that the expression and function of drug transporters at the blood-brain barrier are altered in Alzheimer's disease (AD). However, we recently demonstrated in a mouse model of AD that the expression of key drug transporters and metabolizing enzymes was modified in peripheral organs, such as the small intestine and liver, suggesting that systemic drug absorption may be altered in AD. The purpose of this study was to determine whether the expression of drug transporters in the kidneys differed between 8- to 9-month-old wild-type mice and APPswe/PSEN1dE9 (APP/PS1) transgenic mice, a mouse model of familial AD, using a quantitative targeted absolute proteomics approach. The protein expression of the drug transporters—multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2—was upregulated 1.6-, 1.3-, and 1.4-fold, respectively, in kidneys from APP/PS1 mice relative to wild-type mice. These results suggest that in addition to modified oral absorption of certain drugs, it is possible that the renal excretion of drugs that are multidrug resistance-associated protein 2, organic anion transporter 3, and organic cation transporter 2 substrates could be altered in AD. These changes could affect the interpretation of studies conducted during drug development using this mouse model of AD and potentially impact dosage regimens of such drugs prescribed in this patient population.

KW - Alzheimer's disease

KW - multidrug resistance-associated protein(s) (MDR)

KW - organic anion transporter(s) (OAT)

KW - organic cation transporter(s) (OCT)

KW - renal transport

KW - transporters

UR - http://www.scopus.com/inward/record.url?scp=85063639241&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2019.02.016

DO - 10.1016/j.xphs.2019.02.016

M3 - Article

VL - 108

SP - 2484

EP - 2489

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 7

ER -